INTERCEPT PHARMACEUTICALS, INC. short interest in 2023
In 2023, INTERCEPT PHARMACEUTICALS, INC.'s disclosed short interest ran from 8.51% of shares outstanding on 13 Jan 2023 to 24.26% on 31 Oct 2023, a change of +15.75 percentage points. The year's high was 29.53% on 15 Sep 2023 and its low 6.17% on 15 Feb 2023, averaging 15.24% across 20 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.90 days on 31 Aug 2023. Full history: INTERCEPT PHARMACEUTICALS, INC..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023
2023 in figures
- Start of year
- 8.51% (13 Jan 2023)
- End of year
- 24.26% (31 Oct 2023)
- Change
- +15.75 pp
- High
- 29.53% (15 Sep 2023)
- Low
- 6.17% (15 Feb 2023)
- Average
- 15.24%
- Highest days to cover
- 15.90 (31 Aug 2023)
- SEC filings marked
- 7
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 8.51% | 3.91 | |
| 31 Jan 2023 | 7.60% | 5.00 | |
| 15 Feb 2023 | 6.17% | 3.21 | |
| 28 Feb 2023 | 7.84% | 4.68 | |
| 15 Mar 2023 | 8.02% | 3.84 | 10-K filed, results (8-K) |
| 31 Mar 2023 | 9.32% | 5.53 | |
| 14 Apr 2023 | 9.15% | 4.32 | |
| 28 Apr 2023 | 8.86% | 4.35 | 10-Q filed, results (8-K) |
| 15 May 2023 | 7.68% | 5.14 | |
| 31 May 2023 | 12.40% | 1.83 | |
| 15 Jun 2023 | 15.32% | 5.58 | |
| 30 Jun 2023 | 17.21% | 3.94 | |
| 14 Jul 2023 | 17.90% | 7.45 | |
| 31 Jul 2023 | 20.42% | 13.21 | |
| 15 Aug 2023 | 22.78% | 11.86 | 10-Q filed, results (8-K) |
| 31 Aug 2023 | 24.89% | 15.90 | |
| 15 Sep 2023 | 29.53% | 10.23 | |
| 29 Sep 2023 | 22.57% | 1.61 | |
| 13 Oct 2023 | 24.39% | 4.01 | |
| 31 Oct 2023 | 24.26% | 8.34 |
See also: INTERCEPT PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.